UA76402C2 - Use of brivudine in acute herpes zoster infections and post-herpetic neuralgia - Google Patents
Use of brivudine in acute herpes zoster infections and post-herpetic neuralgia Download PDFInfo
- Publication number
- UA76402C2 UA76402C2 UA2001074658A UA2001074658A UA76402C2 UA 76402 C2 UA76402 C2 UA 76402C2 UA 2001074658 A UA2001074658 A UA 2001074658A UA 2001074658 A UA2001074658 A UA 2001074658A UA 76402 C2 UA76402 C2 UA 76402C2
- Authority
- UA
- Ukraine
- Prior art keywords
- brivudine
- treatment
- patients
- herpes zoster
- acyclovir
- Prior art date
Links
- 229960001169 brivudine Drugs 0.000 title abstract description 51
- ODZBBRURCPAEIQ-PIXDULNESA-N helpin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(\C=C\Br)=C1 ODZBBRURCPAEIQ-PIXDULNESA-N 0.000 title abstract description 51
- 208000007514 Herpes zoster Diseases 0.000 title abstract description 21
- 206010036376 Postherpetic Neuralgia Diseases 0.000 title abstract description 9
- 230000001154 acute effect Effects 0.000 title abstract description 8
- 208000015181 infectious disease Diseases 0.000 title abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 229960004150 aciclovir Drugs 0.000 description 27
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 27
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 208000002193 Pain Diseases 0.000 description 11
- 230000008901 benefit Effects 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010037844 rash Diseases 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960004396 famciclovir Drugs 0.000 description 4
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 3
- 229920001531 copovidone Polymers 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940093257 valacyclovir Drugs 0.000 description 3
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 2
- 229920003080 Povidone K 25 Polymers 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 229960001179 penciclovir Drugs 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 241001516584 Andrya Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI000009A ITMI20010009A1 (it) | 2001-01-03 | 2001-01-03 | Composizioni farmaceutica contenente brivudina per la singola somministrazione giornaliera |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA76402C2 true UA76402C2 (en) | 2006-08-15 |
Family
ID=11446384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001074658A UA76402C2 (en) | 2001-01-03 | 2001-07-04 | Use of brivudine in acute herpes zoster infections and post-herpetic neuralgia |
Country Status (20)
| Country | Link |
|---|---|
| AT (1) | AT6141U1 (es) |
| BE (1) | BE1014522A5 (es) |
| CH (1) | CH695662A5 (es) |
| CZ (1) | CZ20012464A3 (es) |
| DK (1) | DK177084B1 (es) |
| ES (1) | ES2192456B1 (es) |
| FI (1) | FI20011446A (es) |
| FR (1) | FR2818907B1 (es) |
| GB (1) | GB2370771A (es) |
| GR (1) | GR1004012B (es) |
| HR (1) | HRPK20010345B3 (es) |
| HU (1) | HUP0102816A3 (es) |
| IE (1) | IE20010413A1 (es) |
| IT (1) | ITMI20010009A1 (es) |
| NL (1) | NL1018431C2 (es) |
| PL (1) | PL348480A1 (es) |
| PT (1) | PT102642B (es) |
| SE (1) | SE0102309L (es) |
| SK (1) | SK287043B6 (es) |
| UA (1) | UA76402C2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2239527B1 (es) * | 2004-03-01 | 2006-11-16 | M. Cruz Fernandez Gonzalez | Composicion farmacologica de uso topico para el tratamiento del herpes zoster. |
| CN113712928A (zh) * | 2021-09-29 | 2021-11-30 | 重庆市力扬医药开发有限公司 | 经口腔粘膜吸收的溴夫定药物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0104857A1 (en) * | 1982-09-28 | 1984-04-04 | Beecham Group Plc | Deoxyuridine compounds, methods for preparing them and their use in medicine |
| IT1170232B (it) * | 1983-10-31 | 1987-06-03 | Anna Gioia Stendardi | Composizioni terapeutiche ad attivita' antivirale |
| US5446031A (en) * | 1991-04-24 | 1995-08-29 | Yamasa Shuyu Kabushiki Kaisha | 1-β-D-arabinofuranosyl-(E)-5-(2-halogenovinyl)uracil derivatives |
| PT874631E (pt) * | 1996-01-19 | 2004-04-30 | Glaxo Group Ltd | Utilizacao de valaciclovir para a manufactura de um medicamento para o tratamento de herpes genital por aplicacao diaria unica |
-
2001
- 2001-01-03 IT IT2001MI000009A patent/ITMI20010009A1/it unknown
- 2001-04-25 IE IE20010413A patent/IE20010413A1/en not_active IP Right Cessation
- 2001-05-01 GB GB0110682A patent/GB2370771A/en not_active Withdrawn
- 2001-05-11 HR HR20010345A patent/HRPK20010345B3/xx not_active IP Right Cessation
- 2001-05-29 CH CH00987/01A patent/CH695662A5/de not_active IP Right Cessation
- 2001-06-28 SE SE0102309A patent/SE0102309L/ not_active Application Discontinuation
- 2001-06-29 DK DKPA200101019A patent/DK177084B1/da not_active IP Right Cessation
- 2001-06-29 FR FR0108596A patent/FR2818907B1/fr not_active Expired - Lifetime
- 2001-07-02 NL NL1018431A patent/NL1018431C2/nl not_active IP Right Cessation
- 2001-07-03 FI FI20011446A patent/FI20011446A/fi not_active Application Discontinuation
- 2001-07-04 SK SK957-2001A patent/SK287043B6/sk not_active IP Right Cessation
- 2001-07-04 CZ CZ20012464A patent/CZ20012464A3/cs unknown
- 2001-07-04 UA UA2001074658A patent/UA76402C2/uk unknown
- 2001-07-04 BE BE2001/0452A patent/BE1014522A5/fr not_active IP Right Cessation
- 2001-07-05 ES ES200101566A patent/ES2192456B1/es not_active Expired - Fee Related
- 2001-07-05 GR GR20010100322A patent/GR1004012B/el unknown
- 2001-07-05 HU HU0102816A patent/HUP0102816A3/hu unknown
- 2001-07-05 PT PT102642A patent/PT102642B/pt active IP Right Grant
- 2001-07-05 PL PL01348480A patent/PL348480A1/xx not_active Application Discontinuation
-
2002
- 2002-07-03 AT AT0805702U patent/AT6141U1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0102816A2 (en) | 2002-10-28 |
| HU0102816D0 (en) | 2001-09-28 |
| ITMI20010009A1 (it) | 2002-07-03 |
| ITMI20010009A0 (it) | 2001-01-03 |
| BE1014522A5 (fr) | 2003-12-02 |
| SE0102309D0 (sv) | 2001-06-28 |
| CZ20012464A3 (cs) | 2002-08-14 |
| GB0110682D0 (en) | 2001-06-20 |
| AT6141U1 (de) | 2003-05-26 |
| GR1004012B (el) | 2002-11-01 |
| PT102642B (pt) | 2003-06-30 |
| FI20011446A0 (fi) | 2001-07-03 |
| GR20010100322A (el) | 2002-10-08 |
| SK9572001A3 (en) | 2003-03-04 |
| PL348480A1 (en) | 2002-07-15 |
| ES2192456B1 (es) | 2005-02-01 |
| DK200101019A (da) | 2002-07-04 |
| HUP0102816A3 (en) | 2005-01-28 |
| SE0102309L (sv) | 2002-07-04 |
| FI20011446A (fi) | 2002-07-04 |
| HRP20010345A2 (en) | 2003-08-31 |
| PT102642A (pt) | 2002-07-31 |
| FR2818907B1 (fr) | 2006-05-26 |
| FR2818907A1 (fr) | 2002-07-05 |
| ES2192456A1 (es) | 2003-10-01 |
| HRPK20010345B3 (en) | 2005-02-28 |
| DK177084B1 (da) | 2011-07-11 |
| NL1018431C2 (nl) | 2002-07-05 |
| GB2370771A (en) | 2002-07-10 |
| SK287043B6 (sk) | 2009-10-07 |
| IE20010413A1 (en) | 2003-04-16 |
| CH695662A5 (de) | 2006-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Glatthaar-Saalmüller et al. | Antiviral activity in vitro of two preparations of the herbal medicinal product Sinupret® against viruses causing respiratory infections | |
| Bean et al. | Acyclovir therapy for acute herpes zoster | |
| ES2706407T3 (es) | Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona | |
| UA76402C2 (en) | Use of brivudine in acute herpes zoster infections and post-herpetic neuralgia | |
| ES2689042T3 (es) | Uso de 3-n-butil isoindolina cetona en la preparación de fármacos para prevenir y tratar el infarto cerebral | |
| Amsterdam et al. | Suppression of herpes simplex virus infections with oral lithium carbonate—a possible antiviral activity | |
| ES2678122T3 (es) | Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial | |
| US20130190301A1 (en) | Piroxicam for prophylactically and therapeutically treating herpes infections | |
| Pistone et al. | Cutaneous adverse reactions to highly antiretroviral therapy in HIV-positive patients | |
| Berkower et al. | Silicone‐Acyclovir Controlled Release Devices Suppress Primary Herpes Simplex Virus‐2 and Varicella Zoster Virus Infections In Vitro | |
| EP3801532A1 (en) | Formulations of raltegravir | |
| Stepanova et al. | Phleboprotectors based on flavonoids: dosage forms, biopharmaceutical characteristics, technological features | |
| Lindenbaum et al. | Variation in digoxin bioavailability: a continuing problem | |
| Gupta et al. | Emerging bioactive antiviral drugs in the light of epidemics | |
| Labialis | Famciclovir for cutaneous herpesvirus infections: an update and review of new single-day dosing indications | |
| CN114377018B (zh) | 硝呋莫司在制备抗流感病毒药物中的应用 | |
| Worrall | Topical acyclovir for recurrent herpes labialis in primary care: Critical appraisal | |
| DE10130128A1 (de) | Brivudin enthaltende pharmazeutische Zusammensetzung für die einmal tägliche Verabreichung | |
| CN105287618A (zh) | 一种治疗神经性疼痛的口服药物组合物及其应用 | |
| TWI418347B (zh) | 治療疱疹病毒感染的方法 | |
| Chudasama et al. | Study of process of intervention to control leptospirosis through chemoprophylaxis | |
| RU52331U1 (ru) | Аптечка кардиологическая для оказания неотложной само- и взаимопомощи "трикард" | |
| TR2021018192A1 (tr) | Anti̇-vi̇ral etki̇ gösterebi̇lecek yeni̇ i̇laç formülasyonlarinin hazirlanmasi ve covi̇d-19?a karşi etki̇si̇ni̇n araştirilmasi | |
| EP3870167A2 (en) | Pharmaceutical compositions and methods of making on demand solid dosage formulations | |
| RU2234922C2 (ru) | Антигриппозный комплексный препарат |